French gene therapy play Coave rebrands with €21.2M series B extension
Formerly Horama, Coave is developing targeted therapies for CNS, ocular diseases
With €21.2 million ($25.1 million) in additional series B funding backed by a European syndicate, Paris-based Coave plans to advance its pipeline of targeted gene therapies for CNS and rare ocular diseases.
Seroba Life Sciences led the round, which brings the total series B funding raised to €33 million. New investors Théa Open Innovation and eureKARE, and existing investors Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne also participated...